Genentech's Lucentis Heads to FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech is touting the breadth and quality of data for the macular degeneration agent, including two Phase III trials and results showing superiority to Novartis/QLT's Visudyne.